Bicara Therapeutics (BCAX) Free Cash Flow (2023 - 2026)

Bicara Therapeutics' Free Cash Flow history runs 4 years deep, the most recent figure standing at -$37.6 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 33.67% year-over-year to -$37.6 million in Q1 2026; TTM through Mar 2026 was -$116.6 million, a 31.97% decrease from a year earlier, with the FY2025 full-year figure at -$107.1 million, down 43.16% from the prior year.
• Free Cash Flow fell to -$37.6 million in Q1 2026 per BCAX's latest filing, from -$24.1 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$8.5 million in Q4 2023 and bottomed at -$37.6 million in Q1 2026.
• The 4-year median for Free Cash Flow is -$24.9 million (2025), against an average of -$22.8 million.
• Across the five-year window, Free Cash Flow tumbled 254.96% in 2024 and increased 19.78% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$8.5 million in 2023, then tumbled by 254.96% to -$30.1 million in 2024, then gained by 19.78% to -$24.1 million in 2025, then slumped by 55.73% to -$37.6 million in 2026.
• Per Business Quant, the three latest BCAX Free Cash Flow figures stand at -$37.6 million (Q1 2026), -$24.1 million (Q4 2025), and -$29.3 million (Q3 2025).